Naver D2SF backs ImpriMed in $10m Series A2 bridge round
Naver D2SF, NAVER’s venture arm, invested in Silicon Valley precision medicine firm ImpriMed as it joined ImpriMed’s $10 million Series A2 bridge round.
SEOUL, South Korea, Sept. 18, 2026 // -- NAVER D2SF, NAVER's inhouse corporate venture arm, has invested in ImpriMed, a Silicon Valley-based precision medicine company, joining ImpriMed's $10 million Series A2 bridge round. ImpriMed develops AI-driven precision medicine solutions that com…